We're so glad you're here! This site is to help anyone diagnosed with Medullary Thyroid Cancer and their caregivers find valuable information and support. If you'd like to connect with others with MTC, please consider joining our very active Facebook Group. You don't have to go through this alone!
If you don't yet have a copy, please download the American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma, aka "The Guidelines." This is the MTC Bible. Read it and know it and it will help you and your doctor ensure you get the proper treatment.
Lastly, please consider looking into being seen by an MTC expert. We do our best to keep a running list of what we call "Centers of Excellence." These are doctors and facilities that are properly trained and experienced enough to treat MTC patients. It's one of the most important decisions you can make on your journey.
"CHICAGO Eli Lilly's Retevmo (selpercatinib) could be a new option for patients with non-small cell lung cancer to prevent recurrence after ..."
"Eli Lilly and Company announced results from the phase 3 LIBRETTO-432 clinical trial of Retevmo (selpercatinib) as adjuvant therapy versus placebo ..."
"Adjuvant selpercatinib x 3 yrs vs placebo: Stage IIIIIA 2-yr EFS: 92 ... RET fusion+ NSCLC now has a promising adjuvant treatment option with ..."
"... selpercatinib in patients with stage IBIIIA RET fusionpositive nonsmall cell lung cancer (NSCLC) (Abstract LBA3). Sarcoma · The ASCO Post Staff ..."
"A Phase 3 study shows a significantly reduced risk of relapse in a small but clearly defined group of lung cancer patients. In the Phase 3 study, ..."
This website is intended for educational purposes only. It is not intended, nor should it be interpreted, as medical advice or instructions of any kind. Readers are advised to consult their own medical doctor(s) for all matters involving their health and medical care.